106 jobs found in Washington

Bristol Myers Squibb is a global biopharmaceutical company committed to creating innovative medicines for millions of patients around the world fighting serious diseases in therapeutic areas such as oncology, hematology, immunology, cardiovascular and neuroscience. At the same time, we also nurture our own team with inspiring work and challenging career options.

Bristol Myers Squibb is a global biopharmaceutical company committed to creating innovative medicines for millions of patients around the world fighting serious diseases in therapeutic areas such as oncology, hematology, immunology, cardiovascular and neuroscience. At the same time, we also nurture our own team with inspiring work and challenging career options.

Bristol Myers Squibb is a global biopharmaceutical company committed to creating innovative medicines for millions of patients around the world fighting serious diseases in therapeutic areas such as oncology, hematology, immunology, cardiovascular and neuroscience. At the same time, we also nurture our own team with inspiring work and challenging career options.

Bristol Myers Squibb is a global biopharmaceutical company committed to creating innovative medicines for millions of patients around the world fighting serious diseases in therapeutic areas such as oncology, hematology, immunology, cardiovascular and neuroscience. At the same time, we also nurture our own team with inspiring work and challenging career options.

Bristol Myers Squibb is a global biopharmaceutical company committed to creating innovative medicines for millions of patients around the world fighting serious diseases in therapeutic areas such as oncology, hematology, immunology, cardiovascular and neuroscience. At the same time, we also nurture our own team with inspiring work and challenging career options.

For more than 125 years, Boehringer Ingelheim has been committed to the research and development of innovative medicines that help bring more health to patients and their families. As a privately-held, family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in science.

Our desire to make a positive impact on our patients extends to our employees and BioMarin is committed to fostering an inclusive environment where every person feels seen, valued, and heard – so employees can thrive in all areas of their lives, in and outside of work. 

We came to Biogen to make an impact, to transform rigorous science into first-in-class medicines. We stay to create new possibilities together. We strive for excellence and go beyond the expected because we care deeply about making a difference for the many people we serve.

We came to Biogen to make an impact, to transform rigorous science into first-in-class medicines. We stay to create new possibilities together. We strive for excellence and go beyond the expected because we care deeply about making a difference for the many people we serve.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

At Bayer, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve.